Treatment of Schambergs disease with pentoxifylline - therapeutic trial

Thirty patients with schamberg's disease were started on pentoxifylline (400 mg three times daily) for a period of 9 weeks. improvement was assessed at 3 weekly intervals by two observers independently and graded as mild (<25%), moderate (25-50%) and marked (>50%). marked improvement was observed in 15/30 (50%) patients. we conclude that pentoxifylline should be considered as first line therapy in all patients with schamberg's disease.